PARKHOSPS
Micro CapPark Medi World Limited
Pharma
Park Medi World Limited operates a network of 16 multi-super specialty hospitals across 14 cities in 5 states, primarily in North India. It focuses on providing affordable, high-quality healthcare through a cluster-based approach, with 3,960 beds including 1,040 ICU beds, and a comprehensive range of specialty services.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is acceptable, price trend is neutral, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Excellent · 100/100Rev +32% YoY · PAT +67% YoY · margin expansion · +12% QoQ · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹460 Cr | +32.2% | +12.2% |
| EBITDA | ₹127 Cr | +44.3% | +28.3% |
| Operating margin | 28.0% | +300 bps | +400 bps |
| PAT | ₹77 Cr | +67.4% | +45.3% |
| PAT margin | 16.7% | +205 bps | +381 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
Park Medi World reported its 'finest year' in FY'26 with record financial and operating performance. Revenue grew 21% YoY to INR 16,794 Mn, EBITDA rose 20% YoY to INR 4,443 Mn (margin 26.5%), and Net Profit increased 27% YoY to INR 2,736 Mn (margin 16.3%). Bed capacity expanded 20% YoY to 3,610 beds.
The company delivered record financial and operating performance in FY'26, driven by capacity additions and improved utilization. Management's focus on disciplined capital allocation, balance sheet strength, and measured expansion, alongside a clear roadmap for significant bed capacity expansion, supports the ongoing growth thesis.
Speciality Wise Revenue Bifurcation (FY'26)
Latest issuer-disclosed distribution across 9 reported categories.
Network Expansion
Bed capacity is projected to grow by over 50% between FY'26-28, reaching 5,460 beds. Brownfield expansion aims to improve asset utilization and add beds at lower cost.
Inorganic Growth
Focus on North India clusters and adjacent markets, leveraging a strong track record of turnaround and integration to capitalize on fragmented market opportunities.
Asset-Light & Capital-Efficient Growth
Expansion through O&M contracts and partnerships enables faster ramp-up with lower upfront capital intensity, supporting ROCE-accretive growth.
Operational & Clinical Excellence
Investments in advanced medical equipment and robotics, expansion of super-specialties, and complex procedures are improving ARPOB and overall efficiency.
KP Institute of Medical Sciences, Agra
Acquired and commissioned in Feb 2026, adding 360 beds. This was the largest acquisition to date.
Krishna Super Speciality Hospital, Bhatinda
Acquired and commissioned in Jul 2025, adding 250 beds.
Park Hospital, Panchkula
Construction completed for this 350-bed greenfield project, commissioned on Apr 10, 2026.
Febris Hospital, Narela – Delhi
Acquired 200 beds, expected to be commissioned in Q2 FY'27.
Government & Policy Push
Ayushman Bharat (40+ Cr cards, 9+ Cr hospitalizations) and CGHS rate revisions (~10-15% increase) are driving demand and improving access.
Rising Insurance Penetration
Health insurance penetration is expected to increase from 40-42% (FY'24) to 45-50% (FY'26E), improving healthcare accessibility and hospitalization rates.
Increasing Health Awareness
Improving awareness for preventive and curative care due to urbanization, coupled with rising disposable income, is accelerating healthcare demand.
Medical Tourism
India remains a preferred destination for medical tourists due to cost competitiveness and quality care, with recovery visible post-COVID.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The presentation provides both Q4 YoY and full-year (FY) YoY comparisons, which are crucial for assessing both recent momentum and overall annual performance in the healthcare sector. QoQ is also available for Q4 vs Q3, indicating sequential trends.
Revenue (FY'26)
Revenue (ex Other income) increased 21% YoY to INR 16,794 Mn in FY'26. Q4 FY'26 revenue grew 30% YoY to INR 4,604 Mn.
EBITDA (FY'26)
EBITDA grew 20% YoY to INR 4,443 Mn in FY'26, with a margin of 26.5%. Q4 FY'26 EBITDA increased 44% YoY to INR 1,274 Mn, with a margin of 27.7%.
Net Profit (FY'26)
Net Profit increased 27% YoY to INR 2,736 Mn in FY'26, with a margin of 16.3%. Q4 FY'26 Net Profit grew 47% YoY to INR 768 Mn, with a margin of 16.7%.
Bed Capacity (FY'26)
Bed capacity increased 20% YoY to 3,610 beds in FY'26. As of May 2026, total bed capacity is 3,960.
FY'26 Performance
MD Dr. Ankit Gupta stated FY'26 was the 'finest year' with record financial and operating performance, largest-ever capacity addition, and strengthened balance sheet.
Post-IPO Priorities
Immediate priorities include seamless integration of acquired assets, improving utilization across newer facilities, and sustaining profitability through internal accruals.
Medium-Term Strategy
Management will continue to selectively pursue growth opportunities while maintaining commitment to affordable, high-quality healthcare and long-term value creation.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Bed Capacity | 3,960 beds (as of May 2026) | Progress towards 5,460 beds by FY'28, especially commissioning of Narela (Q2 FY'27), Gorakhpur (Apr'27), Kanpur (Dec'26), Mohali (Sep'27), Ambala (Oct'27), and Rohtak (Jan'28). |
| Occupancy % | 64.1% (FY'26) | Ramp-up of utilization across newer facilities and recently commissioned hospitals like Panchkula and Agra to drive revenue and profitability. |
| Net Debt | Negative Net Debt (INR 3,230 Mn) (FY'26) | Maintenance of strong balance sheet and disciplined capital allocation, ensuring internal accruals fund growth and leverage remains comfortable amidst expansion. |
| EBITDA Margin | 26.5% (FY'26) | Sustaining profitability and margins as new capacities are integrated and ramped up, especially given the significant expansion plans. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
51Neutralnear 52W high
Technical chart
PARKHOSPSdaily · 3Y+97.7%Technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 69.
- SMA20 rising (~13.8% over last month) — short-term momentum positive.
- RSI(14) at 69 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 3% of 52-week high — testing resistance.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 9/15 to the score.
- Quality contributes 10/20 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -8.7%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 64th percentile of the scored universe and 51st percentile within Pharma. Main check: cash conversion is weak at 55/100.
Healthy Trust Lite: Promoter holding is 82.9%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 51st pctile, median 70 · Micro: 46th pctile, median 71
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 82.9%.
- ▸Promoter pledge is zero.
- ▸OPM spread across recent quarters is 4%.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 47.40
- P/B
- 6.05
- EV/EBITDA
- 24.88
- Market Cap
- 12226.00Cr
Profitability
- ROE
- 16.70%
- ROCE
- 19.30%
- ROA
- 9.74%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 17.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 10.00%
- EPS 3Y
- 5.00%
Balance Sheet
- Debt/Equity
- 0.34
- Interest Coverage
- 7.53×
- Altman Z
- 5.98
- Book Value
- 46.80
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- 329.00 Cr
- EPS TTM
- 5.98
Shareholding
- Promoter Hold
- 82.89%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 93%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.